The structure of the humanised A33 Fab C226S variant, an immunotherapy candidate for colorectal cancer

DIQMTQSPSSLSASVGDRVTITCKASQNVRTVVAWYQQKPGKAPKTLIYLASNRHTGVPSRFSGSGSGTDFTLTISSLQP
EDFATYFCLQHWSYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

EVQLVESGGGLVQPGGSLRLSCAASGFAFSTYDMSWVRQAPGKGLEWVATISSGGSYTYYLDSVKGRFTISRDSSKNTLY
LQMNSLRAEDTAVYYCAPTTVVPFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSAA

Escherichia coli str. K-12 substr. W3110

monoclonal antibodies, Human A33 Fab, Colorectal cancer therapy, Humanised Fab, IMMUNE SYSTEM

(chain A and (resid 1 through 125 or (resid 126 and (name N or name CA or name C or name O or name CB )) or resid 127 through 144 or (resid 145 and (name N or name CA or name C or name O or name CB )) or resid 146 through 168 or (resid 169 and (name N or name CA or name C or name O or name CB or name CG )) or resid 170 through 213))

(chain B and (resid 1 through 16 or (resid 17 and (name N or name CA or name C or name O or name CB )) or resid 18 through 44 or (resid 45 and (name N or name CA or name C or name O or name CB )) or resid 46 through 141 or (resid 142 through 145 and (name N or name CA or name C or name O or name CB )) or resid 146 through 182 or (resid 183 through 185 and (name N or name CA or name C or name O or name CB )) or resid 186 through 187 or (resid 188 and (name N or name CA or name C or name O or name CB )) or resid 189 through 213))

(chain C and (resid 1 through 61 or (resid 62 and (name N or name CA or name C or name O or name CB )) or resid 63 through 118 or resid 120 through 215 or (resid 216 and (name N or name CA or name C or name O or name CB )) or resid 217))

(chain D and (resid 1 through 118 or resid 120 through 217))